Share on StockTwits

Integra Lifesciences Holdings Corp (NASDAQ:IART) VP Deborah A. Leonetti sold 1,000 shares of the company’s stock on the open market in a transaction dated Friday, August 22nd. The stock was sold at an average price of $50.96, for a total value of $50,960.00. Following the transaction, the vice president now directly owns 9,774 shares in the company, valued at approximately $498,083. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Integra Lifesciences Holdings Corp (NASDAQ:IART) traded down 1.20% on Monday, hitting $50.09. 140,211 shares of the company’s stock traded hands. Integra Lifesciences Holdings Corp has a 52 week low of $37.92 and a 52 week high of $51.32. The stock has a 50-day moving average of $47.97 and a 200-day moving average of $46.61. The company’s market cap is $1.633 billion.

Integra Lifesciences Holdings Corp (NASDAQ:IART) last announced its earnings results on Tuesday, August 5th. The company reported $0.68 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.64 by $0.04. The company had revenue of $231.40 million for the quarter, compared to the consensus estimate of $229.32 million. During the same quarter in the prior year, the company posted $0.60 earnings per share. The company’s quarterly revenue was up 12.6% on a year-over-year basis. On average, analysts predict that Integra Lifesciences Holdings Corp will post $2.94 earnings per share for the current fiscal year.

A number of research firms have recently commented on IART. Analysts at Oppenheimer reiterated an “outperform” rating on shares of Integra Lifesciences Holdings Corp in a research note on Wednesday, August 6th. They now have a $57.00 price target on the stock, up previously from $55.00. Analysts at Jefferies Group raised their price target on shares of Integra Lifesciences Holdings Corp from $54.00 to $57.00 in a research note on Wednesday, August 6th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $52.57.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is an integrated medical technology company.

Receive News & Ratings for Integra Lifesciences Holdings Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences Holdings Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.